Interní Med. 2012; 14(6-7): 246-249

Advanced heart failure care management

MUDr.Marie Lazárová1, doc.MUDr.Filip Málek, Ph.D., MBA2, doc.MUDr.Miloš Táborský, Ph.D., FESC, MBA1
1 I. interní klinika &ndash, kardiologická Fakultní nemocnice Olomouc
2 Kardiovaskulární centrum Nemocnice Na Homolce, Praha

Heart failure (HF) represents a disease with high mortality and morbidity rate. Because of its high prevalence, HF causes big overall economic

and social burden. As the population generally grows older and better diagnostic and treatment methods are being developed in

cardiology, much more patients develop HF. We can offer HF pharmacotherapy and implantable device therapy in order to improve patients

prognosis. Also the development of the whole care system for HF patients is very important, especially establishing specialized clinics

for HF that provide adequate diagnostics, treatment and education of patients in a co-operation with their primary care providers.

Keywords: advanced chronic heart failure, disease management program

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lazárová M, Málek F, Táborský M. Advanced heart failure care management. Interní Med. 2012;14(6-7):246-249.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Špinar J, Vítovec J, Hradec J, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2011. Cor Vasa 2012; 54: v tisku.
    2. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Eur Heart J 2010; 31: 2677-2687. Go to original source... Go to PubMed...
    3. Felker GM, Lee KL, Bull DA, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New Engl J Med 2011; 364: 797-805. Go to original source... Go to PubMed...
    4. Epstein AM, Jha AK, Orav EJ. The Relationship between Hospital Admission Rates and Rehospitalizations. New Engl J Med 2011; 365: 2287-2295. Go to original source... Go to PubMed...
    5. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New Engl J Med 2011; 364: 11-21. Go to original source... Go to PubMed...
    6. Perry G, Brown E, Thornton R, et al. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure: New Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    7. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in Older Patients with Systolic Heart Failure. New Engl J Med 2007; 357: 2248-2261. Go to original source... Go to PubMed...
    8. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trail. Lancet 2008; 372: 1231-1239. Go to original source... Go to PubMed...
    9. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885. Go to original source... Go to PubMed...
    10. Táborský M, Kautzner J, Bytešník J, et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterůdefibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 9: 602-614. Go to original source...
    11. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Eur Heart J 2010; 31: 2677-2687. Go to original source... Go to PubMed...
    12. Tang ASL, Wells GA, Talajic M, et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. New Engl J Med 2010; 363: 2385-2395. Go to original source... Go to PubMed...
    13. Cleland JGF, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death - The trans-European network-home-care system (TEN-HMS) study. J Am Coll Cardiol 2005; 45: 1654-1664. Go to original source... Go to PubMed...
    14. Doval HC, Grancelli HO, Nul D, et al. Randomized trial of telephone intervention in chronic heart failure: DIAL trial. Brit Med J 2005; 331: 425-427. Go to original source... Go to PubMed...
    15. McKelvie RS, Moe GW, Cheung A, et al. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Paliative Care. Can J Cardiol 2011; 27: 319-338. Go to original source... Go to PubMed...
    16. Špinar J, Vítovec J, Hradec J, et al. Doporučení pro diagnostiku a léčbu chronického srdečního selhání ČKS 2011. Cor Vasa 2012; 54: v tisku.
    17. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Eur Heart J 2010; 31: 2677-2687. Go to original source... Go to PubMed...
    18. Felker GM, Lee KL, Bull DA, et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. New Engl J Med 2011; 364: 797-805. Go to original source... Go to PubMed...
    19. Epstein AM, Jha AK, Orav EJ. The Relationship between Hospital Admission Rates and Rehospitalizations. New Engl J Med 2011; 365: 2287-2295. Go to original source... Go to PubMed...
    20. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New Engl J Med 2011; 364: 11-21. Go to original source... Go to PubMed...
    21. Perry G, Brown E, Thornton R, et al. The Effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure: New Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    22. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in Older Patients with Systolic Heart Failure. New Engl J Med 2007; 357: 2248-2261. Go to original source... Go to PubMed...
    23. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trail. Lancet 2008; 372: 1231-1239. Go to original source... Go to PubMed...
    24. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885. Go to original source... Go to PubMed...
    25. Táborský M, Kautzner J, Bytešník J, et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterůdefibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 9: 602-614. Go to original source...
    26. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure. Eur Heart J 2010; 31: 2677-2687. Go to original source... Go to PubMed...
    27. Tang ASL, Wells GA, Talajic M, et al. Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure. New Engl J Med 2010; 363: 2385-2395. Go to original source... Go to PubMed...
    28. Cleland JGF, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death - The trans-European network-home-care system (TEN-HMS) study. J Am Coll Cardiol 2005; 45: 1654-1664. Go to original source... Go to PubMed...
    29. Doval HC, Grancelli HO, Nul D, et al. Randomized trial of telephone intervention in chronic heart failure: DIAL trial. Brit Med J 2005; 331: 425-427. Go to original source... Go to PubMed...
    30. McKelvie RS, Moe GW, Cheung A, et al. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Paliative Care. Can J Cardiol 2011; 27: 319-338. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.